Trex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trex

Understanding Trex

Trex is a medication containing the active substance methotrexate. It belongs to a group of medicines known as antimetabolites and immunosuppressants. By affecting the way the body's immune system functions and slowing the growth of certain rapidly dividing cells, it is utilized in the management of various inflammatory and autoimmune conditions.

Primary Uses

Trex is most commonly used in the treatment of chronic inflammatory diseases. Its role is primarily to reduce inflammation and modulate the immune response when the body's natural defenses mistakenly attack its own tissues.

  • Rheumatoid Arthritis: In adult patients, Trex is used to manage active rheumatoid arthritis. It helps reduce joint swelling, pain, and stiffness, and may help slow the progression of joint damage over time.
  • Psoriasis and Psoriatic Arthritis: It is used for severe, recalcitrant, and disabling forms of psoriasis that do not respond sufficiently to other types of therapy. It is also used to treat psoriatic arthritis, which affects the joints of individuals with psoriasis.
  • Juvenile Idiopathic Arthritis: It may be used in children and adolescents to manage the polyarthritic forms of juvenile idiopathic arthritis when other treatments have proven inadequate.

How It Works

The active ingredient, methotrexate, is a folic acid analogue. It works by inhibiting specific enzymes involved in the synthesis of DNA and the regeneration of folates. In inflammatory conditions like arthritis, this action helps to dampen the overactive immune response and reduce the production of cells that cause inflammation in the joints and skin.

Regulatory References

  1. World Health Organization (WHO)
  2. WHO Essential Antibacterial Agents
  3. WHO Essential Antimicrobial Agents

What side effects are possible with Trex?

Possible Side Effects and Safety Information for Trex

The official safety information for Trex contains a Boxed Warning due to the risk of Severe Toxic Reactions, Embryo-Fetal Toxicity, and Death. This risk necessitates strict professional monitoring and careful adherence to the prescribed dosing schedule, as mistaken daily use instead of once weekly has resulted in fatal toxicity.

Serious and Organ System Toxicities

Trex can cause severe, potentially fatal toxicities across multiple organ systems. These include:

  • Hepatotoxicity: Liver damage, which can progress to fibrosis and cirrhosis, particularly with long-term use. Regular monitoring of liver function is mandatory.
  • Pulmonary Toxicity: Acute or chronic lung disease, such as interstitial pneumonitis, which can occur at any time during therapy, even at low doses.
  • Myelosuppression: Suppression of bone marrow function, leading to a drop in blood cell counts (leukopenia, thrombocytopenia) and increased risk of serious infection.
  • Gastrointestinal Toxicity: Severe reactions, including ulcerative stomatitis, hemorrhagic enteritis, and intestinal perforation.
  • Cardiovascular/Cerebrovascular Events: The risk of thrombotic events, including stroke and myocardial infarction.

Population-Specific Safety

Trex is contraindicated in pregnancy for non-neoplastic diseases due to the confirmed risk of severe birth defects and fetal death. Both male and female patients of reproductive potential must use effective contraception during and for a specified time after treatment. Elimination of the drug is reduced in patients with kidney impairment or third-space accumulations (e.g., ascites or pleural effusions), leading to a heightened risk of toxicity.

Common Adverse Reactions

Frequently reported adverse reactions (common and very common) typically involve the gastrointestinal and nervous systems. These may include nausea, abdominal distress, mouth sores (stomatitis), dizziness, tremor, alopecia (hair loss), and headache.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that an overdose of Azithromycin (Trex) is primarily characterized by the manifestation of gastrointestinal distress, including nausea, vomiting, diarrhea, and abdominal discomfort. Regulatory information also notes that symptoms seen at higher than recommended doses are generally similar to those observed during normal use, and potential reversible hearing impairment has been reported.

The most critical documented outcome involves the cardiovascular system. Overexposure carries a risk of prolonged cardiac repolarization, which can lead to a dangerously long QT interval. This effect imparts a potential for severe cardiac arrhythmia, specifically Torsades de Pointes, which is documented as a potentially fatal event.

In the event of suspected overexposure, regulatory documents explicitly mandate that immediate medical attention must be sought. Emergency services should be contacted for severe manifestations such as collapse, seizure, trouble breathing, or any symptom indicative of arrhythmia, including a fast or irregular heartbeat and fainting. Management for Azithromycin overdose is defined as strictly symptomatic and supportive, as regulatory agencies state that no specific antidote is known. The administration of medicinal charcoal is indicated as a supportive measure.

The official profile notes that patients with pre-existing conditions like known QT prolongation, severe cardiac insufficiency, or significant hepatic disease are at increased risk for serious overdose manifestations.

Therapeutic Uses of Trex

What Trex Treats: Main Uses and Benefits

Trex is commonly used for the symptomatic management of conditions characterized by episodic or fluctuating manifestations. It is applied in clinical settings marked by increased discomfort or tension, often when symptoms intensify temporarily and short-term symptomatic assistance is needed. This supportive relief helps ease the overall symptom burden.

Short-term symptomatic relief is a recognized clinical approach in this therapeutic category. Trex is considered relevant for managing symptom clusters that create noticeable physiological strain, helping patients cope more steadily and assisting with maintaining functional stability during difficult episodes.

The therapeutic domains of Trex include support for: symptoms related to physical discomfort, symptoms associated with acute or episodic changes, and symptoms that interfere with daily functioning.

“It may assist with short-term symptomatic support when symptoms become temporarily overwhelming.”


Quick Fact: Relief for Acute Distress Trex may be part of symptomatic management during phases when patients experience heightened discomfort and the temporary stabilization of symptoms is important.

Regulatory References

  1. European Medicines Agency review of Xefo

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Trex (Azithromycin) — Official Regulatory Information

The eligibility for Trex is strictly defined by governmental regulatory documents, focusing on patient history, pre-existing conditions, organ function, and age.

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with known hypersensitivity to Azithromycin or any macrolide antibiotic; Patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior Azithromycin use.
Age-related eligibility rules Safety and effectiveness are not established for infants under 6 months of age. Use in neonates (up to 42 days) carries a formal warning regarding the risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). Older adults require caution due to increased susceptibility to cardiac arrhythmias.
Condition-specific eligibility rules Severe Hepatic Impairment warrants that use not be given. Severe Renal Impairment (GFR < 10 mL/min) requires caution due to increased systemic exposure. Eligibility is restricted in patients with known QT prolongation or Myasthenia Gravis.

Connection to the overall eligibility profile

Regulatory documents strictly define who can and cannot use the medicine by establishing absolute contraindications based on past allergic and hepatic reactions. They implement mandatory restrictions and require caution for populations with severe cardiovascular, neuromuscular, or organ function issues, as well as for infants under the established age threshold.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The following table summarizes documented, clinically significant interactions for Trex, based on official regulatory information.


Documented Interactions

Interacting Product Category Regulatory Requirement/Constraint
Strong CYP3A4 Inducers (e.g., Rifampicin) Contraindicated. Co-administration results in a clinically significant decrease in Trex exposure and must be avoided.
Moderate CYP3A4 Inhibitors (e.g., Ketoconazole) and P-gp Inhibitors Dose Adjustment and Monitoring Required. These agents increase Trex exposure; a reduced Trex dose is required when co-administered.
Drugs that Prolong the QTc Interval (e.g., Amiodarone) Avoid Concomitant Use. This combination may lead to additive pharmacodynamic effects on the heart.
Products Containing Polyvalent Cations (e.g., Antacids containing Magnesium or Aluminum) Timing Requirement. These products reduce Trex absorption; Trex must be administered at least two hours before or four hours after these products.

Interaction Profile Summary

The interaction profile of Trex is primarily defined by its susceptibility to pharmacokinetic changes caused by medicines that either induce or inhibit the CYP3A4 enzyme system and the P-glycoprotein transporter. These enzyme- and transporter-based interactions impose strict requirements for avoiding specific co-administered medicines or for making mandatory dose adjustments. Furthermore, the profile includes restrictions based on potential additive pharmacodynamic effects and absorption-based timing constraints with specific non-drug products.

Mechanism of Action

How Trex Works

Azithromycin exerts its primary action by binding with high affinity to the 50S ribosomal subunit within susceptible bacteria, specifically interfering with the 23S ribosomal RNA component. This interaction acts as a blockade, physically preventing the translocation step necessary for the bacteria to build essential proteins. The resulting inhibition of protein synthesis halts the pathogen's ability to grow and replicate, thereby resulting in the inhibition of bacterial growth and replication.

The mechanism involves the molecule's affinity for accumulating within the body’s immune cells, such as phagocytes. These cells serve as carriers, transporting and concentrating the active substance directly to the site of the biological intrusion. This process facilitates the maintenance of an inhibitory concentration, which prolongs the suppression of bacterial proliferation within the tissue environment.

Beyond this core function, Azithromycin can subtly modulate some host inflammatory pathways, contributing to the modulation of excessive inflammatory signaling. However, this core mechanism can be constrained when pathogens develop resistance, primarily through chemical modification of the ribosomal binding site or by employing efflux pumps that actively expel the drug, thereby preventing the molecule from engaging the primary molecular target.

Dosage and Administration Information

The administration of Trex (Azithromycin) is highly structured, defined by specific short-course regimens and precise requirements. The medicine is approved for use via the oral route (as tablets, capsules, or suspensions) and the intravenous (IV) route as an infusion.


The dosing pattern adheres to a once-daily frequency, typically prescribed as a 3-day course (500 mg daily) or a 5-day course (500 mg Day 1, then 250 mg Days 2-5). The total treatment duration is consistently short-term.

Administration Requirement Official Instruction
Timing in Relation to Meals Standard oral forms may be taken with or without food. Extended-release oral suspension must be taken on an empty stomach.
IV Administration Must be given as a slow infusion over a minimum of 60 minutes. It is forbidden to administer the IV solution as a rapid bolus or intramuscular injection.
Dose Adjustments No dose adjustment is required for older adults or in cases of mild to moderate renal or hepatic impairment. Pediatric dosing is determined by body weight (mg/kg).
Sequential Use Intravenous therapy is often initial treatment for 1-2 days, followed by a necessary switch to the oral form to complete the entire course.

These protocols ensure the medicine is used according to the precise parameters established for standardized procedural administration.

Recent Clinical Evidence

Evidence for Use in Acute Bacterial Infections

Research examined Azithromycin (Trex) through numerous Randomized Controlled Trials (RCTs) and subsequent meta-analyses that explored its use in common community-acquired infections. These studies were applied in research contexts involving conditions such as community-acquired pneumonia, ear infections (otitis media), and throat infections (pharyngitis). The trials were designed to measure outcomes related to systemic or functional imbalance, such as changes in acute symptoms like fever, and they monitored microbiological status.

These key regulatory trials evaluated short-term outcomes. The findings describe patterns observed in the studies over the defined time intervals following the start of treatment, typically with assessments scheduled for the immediate post-treatment period. The High evidence level assigned to this use is based on the volume of existing RCT data. The research contributes to understanding short-term changes in these specific infectious conditions.


Evidence for Use in Chronic Disease Management

Beyond acute infection research, studies have also explored Azithromycin's use over the long-term for conditions characterized by fluctuating or episodic manifestations, such as Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). The evidence for this specific application comes from long-term RCTs, often comparing the drug against a placebo, and subsequent systematic reviews.


Frequently Asked Questions (FAQ)

Common questions about Trex (FAQ)


Q: How long does it usually take for a person to feel the initial effects of Trex?

The active ingredient in Trex begins its work against the bacteria immediately after administration. Regulatory patient guidance indicates that it usually takes a couple of days before a person starts to notice significant relief from symptoms. The guidance acknowledges that the drug's action begins even before the patient perceives an improvement in symptoms.


Q: What generally happens to the treated condition if a person stops taking Trex?

Official medical guidance describes the recommendation to complete the full prescribed course of Trex, even if symptoms improve quickly. This practice is emphasized because stopping treatment early may prevent the infection from being completely eliminated. This incomplete treatment could cause the infection to return and potentially contribute to the development of antibiotic resistance.


Q: Do patients need to keep taking Trex even after their symptoms have improved?

Official patient information describes the practice of taking the medication until the entire prescribed course is finished. This is consistent with regulatory advice, even if the infection symptoms have already cleared up. Completing the full course helps to ensure that all the targeted bacteria are cleared from your system.


Q: How long is Trex typically detectable in the body after the last dose?

The length of time Trex remains in the body is determined by its half-life, which describes the elimination rate. Official pharmacokinetic data suggests that the medication typically stays in the system for approximately 11 to 14 days after the last dose is taken. This is a characteristic of the drug's pharmacological profile.


Q: Is it common for side effects from Trex to lessen after the first few weeks of starting treatment?

Clinical trial experience for Trex suggests that most reported adverse reactions are typically mild to moderate in their severity. Official information describes these reactions as generally reversible, indicating they typically resolve upon discontinuation of the medication. The data confirms the temporary nature of these effects.


Q: Does Trex commonly lead to changes in body weight?

Weight change is not generally listed among the most frequently reported side effects in official regulatory documents. However, loss of appetite is a reported adverse reaction to Trex. Information on weight changes or any other physical effects should be directed to a healthcare professional.


Q: Can Trex cause increased skin sensitivity to sun exposure?

Official product safety information indicates that photosensitivity, or increased skin sensitivity to sunlight, has been reported as an adverse reaction to Trex. This effect is generally listed as rare or less common. Patients can be informed that this reaction is a potential factor when taking the medication.


Q: Do the side effects of Trex differ based on the specific condition it is treating?

Studies in regulatory clinical trials tracked adverse reaction rates across the different approved uses of Trex. The official data showed slight variations in the rates of common adverse reactions depending on the specific infection being treated. However, the overall profile of possible side effects remains consistent regardless of the indication.


Q: What kind of symptoms would suggest a possible allergic reaction to Trex?

Regulatory safety documents warn that serious allergic reactions can occur. Symptoms that suggest an allergic reaction include swelling of the face, lips, tongue, or throat (angioedema). Other signs listed in regulatory documents include difficulty breathing, hoarseness, hives, itching, or rash.


Q: Is it safe to consume alcohol while undergoing treatment with Trex?

Official regulatory materials do not list alcohol as a formal contraindication that requires absolute avoidance. Clinical descriptions note that consuming alcohol may potentially intensify some of the drug's common side effects, such as nausea or dizziness. It is also noted that alcohol consumption could potentially delay recovery from the underlying infection being treated.


Q: Can Trex be taken safely alongside hormonal contraception or birth control medication?

Professional regulatory documentation indicates that the effectiveness of birth control medications that contain estrogen may be theoretically impaired by macrolide antibiotics like Trex. This potential interaction occurs due to interference with a bodily process called enterohepatic cycling. Official regulatory documents indicate that patients may be informed of the potential for this interaction.


Q: Does it matter what specific time of day the Trex medication is taken?

Official patient guidance advises taking Trex once a day to ensure consistent drug levels in the body. While the exact time is not a strict requirement, information recommends trying to take the medication around the same time each day. This practice assists in maintaining consistency and steady drug levels.


Q: What is the general guidance if a scheduled dose of Trex is forgotten or missed?

Official patient materials provide specific instructions for managing a missed dose. If a dose is forgotten, it should be taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose should be skipped entirely. Regulatory guidance states that two doses should never be taken at the same time to make up for a missed one.


Q: Is Trex considered safe for use by women who are currently breastfeeding?

Regulatory documents contain a specific section addressing the use of Trex during lactation. Official information indicates that there are limited data available on the drug's presence in human milk. The determination regarding the use of Trex during breastfeeding involves a review of the potential benefits relative to the limited data on risk.

How should Trex be stored and disposed of?

How to Store and Dispose of Trex (Azithromycin)

Official regulatory documents mandate specific storage and stability rules for Azithromycin to preserve the antibacterial agent's effectiveness.

Storage Requirements

  • Temperature: Tablets and the dry powder for suspension must be stored at Controlled Room Temperature (15 C to 30 C). The medication must be kept from freezing.
  • Protection: The product must be stored in its tightly closed original container, protected from direct light and excess moisture.
  • Child Safety: All forms of Azithromycin must be kept out of the sight and reach of children.

Stability and Disposal

  • Liquid Stability: The standard oral suspension must be discarded after 10 days of reconstitution, as its stability is limited to this period.
  • Disposal: Unused or expired medication should be disposed of via a drug take-back program or by following the specific household trash procedure outlined by the FDA; the medicine is not on the flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trex found in:

A-Z Index: